Literature DB >> 19361349

The paraoxonase gene family and atherosclerosis.

David Seo1, Pascal Goldschmidt-Clermont.   

Abstract

Management of serum low-density lipoprotein has been a cornerstone of cardiovascular medicine for the past two decades. More recently, the attention paid to the protective role of high-density lipoprotein (HDL) in atherosclerosis has increased substantially, particularly with respect to the antioxidant properties of HDL. Considerable evidence supports the notion that the paraoxonase gene family is largely responsible for the antioxidant properties of HDL. This article reviews the three known members of the paraoxonase family and the evidence that supports their likely role in the development and progression of atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19361349     DOI: 10.1007/s11883-009-0029-3

Source DB:  PubMed          Journal:  Curr Atheroscler Rep        ISSN: 1523-3804            Impact factor:   5.113


  64 in total

Review 1.  Assessing low levels of high-density lipoprotein cholesterol as a risk factor in coronary heart disease: a working group report and update.

Authors:  Antonio M Gotto; Eliot A Brinton
Journal:  J Am Coll Cardiol       Date:  2004-03-03       Impact factor: 24.094

2.  Interrelationship of smoking, paraoxonase activity, and leisure time physical activity: a population-based study.

Authors:  Mariano Senti;; Marta Tomás; Roger Anglada; Roberto Elosua; Jaume Marrugat; Mari;a Isabel Covas; Montserrat Fitó
Journal:  Eur J Intern Med       Date:  2003-05       Impact factor: 4.487

Review 3.  Genome-wide association study to identify SNPs conferring risk of myocardial infarction and their functional analyses.

Authors:  K Ozaki; T Tanaka
Journal:  Cell Mol Life Sci       Date:  2005-08       Impact factor: 9.261

4.  Human paraoxonase-3 is an HDL-associated enzyme with biological activity similar to paraoxonase-1 protein but is not regulated by oxidized lipids.

Authors:  S T Reddy; D J Wadleigh; V Grijalva; C Ng; S Hama; A Gangopadhyay; D M Shih; A J Lusis; M Navab; A M Fogelman
Journal:  Arterioscler Thromb Vasc Biol       Date:  2001-04       Impact factor: 8.311

5.  Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase.

Authors:  M Aviram; M Rosenblat; C L Bisgaier; R S Newton; S L Primo-Parmo; B N La Du
Journal:  J Clin Invest       Date:  1998-04-15       Impact factor: 14.808

6.  Effect of torcetrapib on the progression of coronary atherosclerosis.

Authors:  Steven E Nissen; Jean-Claude Tardif; Stephen J Nicholls; James H Revkin; Charles L Shear; William T Duggan; Witold Ruzyllo; William B Bachinsky; Gabriel P Lasala; Gregory P Lasala; E Murat Tuzcu
Journal:  N Engl J Med       Date:  2007-03-26       Impact factor: 91.245

7.  The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family.

Authors:  S L Primo-Parmo; R C Sorenson; J Teiber; B N La Du
Journal:  Genomics       Date:  1996-05-01       Impact factor: 5.736

8.  Paraoxonase activity in the serum and hepatic mRNA levels decrease during the acute phase response.

Authors:  K R Feingold; R A Memon; A H Moser; C Grunfeld
Journal:  Atherosclerosis       Date:  1998-08       Impact factor: 5.162

9.  Gln-Arg192 polymorphism of paraoxonase 1 is associated with carotid intima-media thickness in patients of type 2 diabetes mellitus of Chinese.

Authors:  YaoMin Hu; HaoMing Tian; Rui Liu
Journal:  Diabetes Res Clin Pract       Date:  2003-07       Impact factor: 5.602

10.  Effect of platelet activating factor-acetylhydrolase on the formation and action of minimally oxidized low density lipoprotein.

Authors:  A D Watson; M Navab; S Y Hama; A Sevanian; S M Prescott; D M Stafforini; T M McIntyre; B N Du; A M Fogelman; J A Berliner
Journal:  J Clin Invest       Date:  1995-02       Impact factor: 14.808

View more
  7 in total

Review 1.  Paraoxonase 1, atherosclerosis and arterial stiffness in renal patients.

Authors:  Ozkan Gungor; Fatih Kircelli; Huseyin Toz
Journal:  Int Urol Nephrol       Date:  2012-06-06       Impact factor: 2.370

2.  Comparative modeling of PON2 and analysis of its substrate binding interactions using computational methods.

Authors:  Subramanian Barathi; Muralidaran Charanya; Shivashanmugam Muthukumaran; Narayanasamy Angayarkanni; Vetrivel Umashankar
Journal:  J Ocul Biol Dis Infor       Date:  2011-02-09

3.  Association between PON1 L55M polymorphism and ischemic stroke: a systematic review and meta-analysis.

Authors:  Peng Shao; Da-Jun Qu; Rui-Ying Song; Ming-Lu Chen; Li-Hua Wang
Journal:  Int J Clin Exp Med       Date:  2015-03-15

4.  Paraoxonase 1 polymorphism and prenatal pesticide exposure associated with adverse cardiovascular risk profiles at school age.

Authors:  Helle R Andersen; Christine Wohlfahrt-Veje; Christine Dalgård; Lene Christiansen; Katharina M Main; Christine Nellemann; Katsuyuki Murata; Tina K Jensen; Niels E Skakkebæk; Philippe Grandjean
Journal:  PLoS One       Date:  2012-05-15       Impact factor: 3.240

5.  Association between paraoxonases gene expression and oxidative stress in hepatotoxicity induced by CCl4.

Authors:  Mohamed M Hafez; Othman A Al-Shabanah; Naif O Al-Harbi; Mohamed M Al-Harbi; Salim S Al-Rejaie; Saad M Alsurayea; Mohamed M Sayed-Ahmed
Journal:  Oxid Med Cell Longev       Date:  2014-11-17       Impact factor: 6.543

6.  Paraoxonase-1 gene Q192R and L55M polymorphisms and risk of cardiovascular disease in Egyptian patients with type 2 diabetes mellitus.

Authors:  Dalia El-Lebedy; Mona Kafoury; Dalia Abd-El Haleem; Alshaymaa Ibrahim; Eman Awadallah; Ingy Ashmawy
Journal:  J Diabetes Metab Disord       Date:  2014-12-20

7.  Interaction between prenatal pesticide exposure and a common polymorphism in the PON1 gene on DNA methylation in genes associated with cardio-metabolic disease risk-an exploratory study.

Authors:  Ken Declerck; Sylvie Remy; Christine Wohlfahrt-Veje; Katharina M Main; Guy Van Camp; Greet Schoeters; Wim Vanden Berghe; Helle R Andersen
Journal:  Clin Epigenetics       Date:  2017-04-05       Impact factor: 6.551

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.